MCK · Intrinsic value
Is McKesson Corporation (MCK) overvalued or undervalued?
McKesson Corporation (MCK) trades at the delayed market price of $1,004.84 a share. That price already implies revenue growth of 5.4% a year for 5 years. TickerWorth's fair value is $938.39 a share (7% above fair value), as of Oct 19, 2026. It is a model estimate, and every input behind it is sourced below.
Model by Miraaj Patel · generated from SEC filings and market data · Updated Oct 19, 2026 · How these pages are made
Is MCK overvalued?
- Fair value
- $938.39
- Market price
- $1,004.84
- Downside to fair value
- 6.6%
- Verdict
- 7% above fair value
Reverse DCF: Today's price implies revenue growth of 5.4% a year for 5 years; our model assumes 6.3% a year on average over the same horizon.
What is MCK's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in US
Its strongest point: looks cheap on the numbers. Its weakest: profitability is weak.
- Value · 67 of 100
Cheaper than 67% of Healthcare companies in US
- Price vs worth · 45 of 100
- Quality · 21 of 100
More profitable than 21% of Healthcare companies in US
- Financial health · 36 of 100
Financially stronger than 36% of Healthcare companies in US
- Growth · 34 of 100
Growing faster than 34% of Healthcare companies in US
- Momentum · 87 of 100
Outperformed 87% of Healthcare companies in US over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
MCK DCF valuation: what the price assumes
At a recent price of $1,005, McKesson Corporation (MCK) trades 7% above TickerWorth's blended fair value of $938.39 per share — a discounted-cash-flow model cross-checked against peer multiples and asset value — meaning the market currently prices MCK overvalued vs our estimate of what the business is intrinsically worth. Our fair value sits below the market, an implied -6.6% move to close the gap if the business performs in line with our assumptions. This is an educational model, not a price target or a recommendation — the value moves with the inputs, which you can test yourself using the WACC slider below.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values MCK at about $908.10 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts McKesson Corporation's projected free cash flows at a weighted-average cost of capital (WACC) of 7.0%, with a long-run terminal growth rate of 2.5%. About 81% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 5.4% annual revenue growth for MCK. Our base case instead compounds to about 6.3% a year over the same forecast, so the market's implied growth is broadly in line with our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, MCK's modeled DCF value ranges from about $596.25 to $2,005 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what McKesson Corporation would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of MCK's intrinsic value. Figures update as new filings and prices come in.
Every input behind MCK's DCF
| Input | Value |
|---|---|
| Base-year revenueMcKESSON CORPORATION FY2026 10-K (accession 0000927653-26-000069): us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, FY2026 full year. | $403,430,000,000 |
| Base EBIT marginMcKESSON CORPORATION FY2026 10-K (accession 0000927653-26-000069): us-gaap:OperatingIncomeLoss 6,212,000,000 / revenue 403,430,000,000 = 1.54%, FY2026. | 1.5% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 9% → 7% → 6% → 5% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.40 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesMcKESSON CORPORATION FY2026 10-K (accession 0000927653-26-000069): WeightedAverageNumberOfDilutedSharesOutstanding = 124,100,000 shares, FY2026. | 124M |
| Market priceBackup price feed · as of 2026-10-19 13:20 UTC | $1,005 |
Change MCK's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does McKesson Corporation do?
What does it do?
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. It operates in the Medical Distribution industry (Healthcare sector), headquartered in United States. The company employs roughly 41,600 people.
How does it make money?
The business turns $411.0B in annual revenue into profit. Out of every $100 of sales, about $1 is left as operating profit (operating margin of 1.3%), after a 4% gross margin on the products/services it sells. After all costs, taxes and interest, 1.1% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks stretched: may struggle to cover its short-term bills (0.9× current ratio), and is currently profitable.
Who at MCK filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Rutledge Napoleon B JR | SVP, Controller & CAO | Open-market sale | $98,950.95 | Form 4 for Rutledge Napoleon B JR (opens sec.gov in a new tab) | |
| Lerman Bradley E | Director | Open-market sale | $268,589.83 | Form 4 for Lerman Bradley E (opens sec.gov in a new tab) | |
| Wilson-Thompson Kathleen | Director | Grant / award | $225,489.08 | Form 4 for Wilson-Thompson Kathleen (opens sec.gov in a new tab) | |
| Caruso Dominic J | Director | Grant / award | $225,489.08 | Form 4 for Caruso Dominic J (opens sec.gov in a new tab) | |
| Martinez Maria | Director | Grant / award | $225,489.08 | Form 4 for Martinez Maria (opens sec.gov in a new tab) | |
| TYLER BRIAN S. | Director, Chief Executive Officer | Open-market sale | $6,715,898.28 | Form 4 for TYLER BRIAN S. (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is MCK's intrinsic value?
TickerWorth's blended fair value for McKesson Corporation (MCK) is $938.39 per share, versus a market price of $1,005 (7% above fair value).
Is MCK overvalued or undervalued?
On our blended fair value MCK looks overvalued vs fair value at $1,005. This is an educational estimate, not advice.
What discount rate is used for MCK?
A WACC of 7.0% and a terminal growth rate of 2.5%.
Is McKesson stock undervalued?
TickerWorth's fair value for McKesson Corporation (MCK) is $938.39 against a market price of $1,004.84. Our read: 7% above fair value. This is a model estimate, not investment advice.
McKesson (MCK) DCF valuation and fair value
Our fair value for McKesson Corporation (MCK) is $938.39, built on a 7.0% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into McKesson stock?
Today's price implies revenue growth of 5.4% a year for 5 years; our model assumes 6.3% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $1,004.84. A model estimate, not investment advice.
McKesson (MCK) insider trading
The most recent insider filing (SEC Form 4) for McKesson Corporation (MCK): Rutledge Napoleon B JR, SVP, Controller & CAO, open-market sale on 2026-09-08. The latest filings are listed on this page. A disclosure, not a signal to trade.
Stocks below our fair value instead
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.